Popular Searches
Diphenyleneiodonium chlorideEpacadostatGilteritinibDinaciclibRo-3306
TargetMol | Star Product
Wikimole
TargetMol | New Product
New Product
TargetMol | Compound Library
Compound Library
Contact UsQuotation
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPRelated productsBioactivityChemical infoStorage&SolubilityCalculator

Degarelix

😃Good
Catalog No. T10988Cas No. 214766-78-6
Alias FE200486 free base, FE 200486 free base

Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.

Degarelix
Other Forms of Degarelix:
Degarelix acetate(214766-78-6 free base)T10988L934016-19-0
In Stock
View details

Degarelix

😃Good
Purity: 99.34%
Catalog No. T10988Alias FE200486 free base, FE 200486 free baseCas No. 214766-78-6
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
Pack SizePriceAvailabilityQuantity
1 mg$60In Stock
5 mg$147In Stock
10 mg$247In Stock
25 mg$393In Stock
50 mg$553In Stock
100 mg$868In Stock
200 mg$1,1707-10 days
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Batch Information

Select Batch
Purity:99.34%
Contact us for more batch information

Resource Download

COA MS HPLC

Product Introduction

Bioactivity
Description
Degarelix is a peptide and selective GnRH (human gonadotropin-releasing hormone) receptor antagonist that treats prostate cancer by lowering testosterone levels in the body.
In vitro
Degarelix significantly reduced cell viability in multiple prostate-derived cell lines (1 nM–10 μM, 0–72 h), with no inhibitory effect on PC-3 cells[1].Degarelix suppressed prostate cell growth by inducing apoptosis (10 μM, 0–72 h)[1].
In vivo
In rats, a single subcutaneous dose of Degarelix (1–10 mg/kg, sc) caused dose-dependent testosterone suppression lasting >30 days[1].In prostate cancer patients, Degarelix (240 mg loading dose followed by monthly 80 mg sc) rapidly reduced serum testosterone to castrate levels (≤0.5 ng/mL), without the agonist-related hormone surge, and maintained suppression for at least 1 month[1].
SynonymsFE200486 free base, FE 200486 free base
Chemical Properties
Molecular Weight1632.26
FormulaC82H103ClN18O16
Cas No.214766-78-6
SmilesC([C@@H](NC([C@@H](NC([C@@H](CC1=CC=C(NC(N)=O)C=C1)NC([C@H](CC2=CC=C(NC(=O)[C@@H]3CC(=O)NC(=O)N3)C=C2)NC([C@@H](NC([C@@H](CC=4C=CC=NC4)NC([C@@H](CC5=CC=C(Cl)C=C5)NC([C@@H](CC6=CC7=C(C=C6)C=CC=C7)NC(C)=O)=O)=O)=O)CO)=O)=O)=O)CC(C)C)=O)CCCCNC(C)C)(=O)N8[C@H](C(N[C@@H](C(N)=O)C)=O)CCC8
Relative Density.1.325 g/cm3 (Predicted)
SequenceAc-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Phe(4-S-dihydroorotamido)-D-Phe(4-ureido)-Leu-Lys(iPr)-Pro-D-Ala-NH2
Sequence ShortXXXSXXLXPA
Storage & Solubility Information
Storagekeep away from moisture | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 4 mg/mL (2.45 mM), Sonication is recommended.
DMSO: 8 mg/mL (4.9 mM), Sonication is recommended.
Solution Preparation Table
H2O/DMSO
1mg5mg10mg50mg
1 mM0.6126 mL3.0632 mL6.1265 mL30.6324 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

GNRHReceptorGnRHRGNRH ReceptorDegarelix
Related Tags: buy Degarelix | purchase Degarelix | Degarelix cost | order Degarelix | Degarelix chemical structure | Degarelix in vivo | Degarelix in vitro | Degarelix formula | Degarelix molecular weight
TargetMol | Logo

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.